

Clinical Trial Summary

January 2025

Better Health, Brighter Future

Overview of Clinical Trials




		LCM ¹		NME ²
GASTROINTESTINAL AND INFLAMMATION		ENTYVIO IV – Pediatric CD/UC ENTYVIO IV – UC Combo Induction ENTYVIO IV – CD Combo Induction ENTYVIO IV – Optimal Treatment Target ADZYNMA (TAK-755) – cTTP, iTTP Maralixibat – PFIC, ALGS	Zasocitinib – Plaque Psoriasis x2 Zasocitinib – Active Psoriatic Arthritis Zasocitinib – Crohn's Disease, UC Mezagitamab – ITP, IgAN Fazirsiran – AATD Assoc. Liver Disease TAK-227 – Active Celiac Disease	Zamaglutenase – Active Celiac Disease TAK-101 – Celiac Disease TAK-004 – Nausea & Vomiting
NEUROSCIENCE	Ŵ		Oveporexton (TAK-861) – NT1, NT2 Danavorexton – OSA, Postanesthesia Recovery TAK-341 – Multiple System Atrophy	TAK-594 – Frontotemporal Dementia
ONCOLOGY	స్థో	ICLUSIG – CML ICLUSIG – 1L Ph+ ALL NINLARO – In-class Transition (MM6) Mirvetuximab – PROC, PSOC	Rusfertide – Polycythemia Vera Dazostinag – Solid Tumors TAK-186 – EGFR+ Solid Tumors TAK-280 – B7-H3+ Solid Tumors	TAK-012 – AML
OTHER RARE DISEASES	-fas	ADYNOVATE – Pediatric HemA, HemA China VONVENDI – Pediatric vWD LIVTENCITY – Pediatric CMV Infection Post Transplant		
PLASMA-DERIVED THERAPIES	\bigcirc	HYQVIA – PID, CIDP/MMN Japan TAK-881 – PID TAK-330 - Prothromplex – DOAC Reversal GLOVENIN-I – AE Japan		
VACCINES	HET.	QDENGA – Dengue Vaccine		

LCM: Life cycle management programs or marketed assets in development seeking new indications, new geographic expansions, fulfillment of regulatory requirements, new formulations/method of use, and/or enhancement in commercial/competitive profile.
 NME: New molecular entity

Overview of Clinical Trials





Study	<u>NCT04779320</u>	<u>NCT04779307</u>
Indication	Crohn's disease in pediatric patients	Ulcerative colitis in pediatric patients
Phase	Phase III	Phase III
# of Patients	N = 120	N = 120
Target Patients	Pediatric patients with Crohn's disease between 2 to 17 years old at the time of randomization for Study NCT04779320	Pediatric patients with ulcerative colitis between 2 to 17 years old at the time of randomization for Study NCT04779307
Arms/ Intervention	 Induction period: Subjects ≥30 kg will receive open–label vedolizumab, 300 mg IV Subjects >15 to <30kg open–label vedolizumab, 200 mg IV Subjects 10 to 15 kg open–label vedolizumab 150 mg IV Maintenance period: ≥30 kg weight cohort): Vedolizumab IV 300 mg or 150 mg (Q8W) >15 <30 kg weight cohort: Vedolizumab IV 200 mg or 100 mg (Q8W) 10 to 15 kg weight cohort: Vedolizumab IV 150 mg or 100 mg (Q8W) 	 Induction period: Subjects ≥30 kg will receive open–label vedolizumab, 300 mg IV Subjects >15 to <30kg open–label vedolizumab, 200 mg IV Subjects 10 to 15 kg open–label vedolizumab 150 mg IV Maintenance period: ≥30 kg weight cohort): Vedolizumab IV 300 mg or 150 mg (Q8W) >15 <30 kg weight cohort: Vedolizumab IV 200 mg or 100 mg (Q8W) 10 to 15 kg weight cohort: Vedolizumab IV 150 mg or 100 mg (Q8W)
Primary endpoint and key secondary endpoint(s)	 Primary: Co-primary 1 (based on PCDAI): Clinical remission at Week 54 Co-primary 2 : Endoscopic response at Week 54 Secondary: Clinical and endoscopic remission at Week 14 Clinical and endoscopic remission at Week 54 Sustained clinical and endoscopic remission at Week 54 Corticosteroid-free remission at Week 54 PK/AVA 	 Primary: Clinical remission at Week 54, based on the modified Mayo score Secondary: Clinical remission at Week 14 Sustained clinical remission at Week 54 Sustained endoscopic remission Endoscopic response at Week 14 and at Week 54 Corticosteroid-free clinical remission at Week 54 PK/AVA
Study start date	April 2022	October 2021

Study	<u>NCT06095128</u>	<u>NCT04259138</u> ¹
Indication	Ulcerative colitis (UC)	Ulcerative Colitis (UC)
Phase	Phase IV ExiGem	Phase IV VERDICT
# of Patients	N = 65	N = 660
Target Patients	Adult (18 to 65) patients with moderate to severely active ulcerative colitis who have failed no more than 2 TNF antagonists.	Moderately to severely active UC
Arms/ Intervention	 Vedolizumab (IV) 300 mg + Tofacitinib (PO) 10 mg Participants will receive Vedolizumab 300 mg , intravenous (IV) infusion, at Week 0, Week 2 and Week 6 along with Tofacitinib 10 mg, tablets, orally, twice daily from Week 0 to Week 8. Participants with clinical response at Week 8 will transition to receive vedolizumab 300 mg IV infusion every 8 weeks (Q8W) through Week 46. 	 Participants will be randomized to 1 of 3 groups, each with a different treatment target. Treatment targets will be defined as: Group 1: corticosteroid-free symptomatic remission Group 2: corticosteroid-free endoscopic + symptomatic remission Group 3: corticosteroid-free histological + endoscopic + symptomatic remission Participants will be assigned a treatment algorithm (A,B, or C) based on their existing UC treatment at the time of entry. Treatment algorithms may include the use of vedolizumab.
Primary endpoint and key secondary endpoint(s)	 Percentage of Participants Achieving Clinical Remission at Week 8 Based on Complete Mayo Score Clinical remission based on complete Mayo Score is where a participant achieves complete Mayo Score ≤2 points with no individual subscore >1 at Week 8. 	Difference in Time to UC-related Complication Between Treatment Target Groups 1 and 3 (Time Frame: From the date of treatment target achievement until the date of first UC-related complication until end of study (Week 96), whichever came first)
Study start date	January 2024	September 2020

GASTROINTESTINAL AND INFLAMMATION

Study	<u>NCT06045754</u>
Indication	Crohn's disease (CD)
Phase	Phase IV EXPLORER 2.0
# of Patients	N = 150
Target Patients	Adults (18 to 65) with moderate to severe Crohn's disease who have experienced inadequate response, loss of response or intolerance to either one prior interleukin [IL] antagonist (Cohort 1) or tumor necrosis factor inhibitor [TNFi] (Cohort 2).
Arms/Intervention	 Part A, Cohort 1: Vedolizumab + Adalimumab Participants will receive vedolizumab IV 300 mg, at Weeks 0, 2, and 6, then every 8 weeks (Q8W) until Week 22 and adalimumab SC 160, 80, and 40 mg at Weeks 0, 2, and 4, respectively, then 40 mg every 2 weeks (Q2W) until Week 26. Part A, Cohort 2: Vedolizumab + Ustekinumab Participants will receive vedolizumab IV 300 mg, at Weeks 0, 2, and 6, then Q8W until Week 22 and ustekinumab IV 520, 390, or 260 mg (weight-based), then SC 90 mg 8 weeks after initial IV dose, then Q8W until Week 24. Part B: Vedolizumab Monotherapy Participants who achieve clinical remission in Part A will receive vedolizumab IV 300 mg monotherapy, Q8W from Week 30 until Week 46.
Primary endpoints	 Part A: Percentage of Participants Achieving Clinical Remission Based on the Crohn's Disease Activity Index (CDAI) at Week 26 Clinical remission is defined as a CDAI score of ≤150 points. Part B: Percentage of Participants in Clinical Remission Based on the CDAI at Week 52 Clinical remission is defined as a CDAI score of ≤150 points.
Study start date	April 2024

Study	<u>NCT06227910</u>	
Indication	Crohn's Disease (CD)	
Phase	Phase IIIb VICTRIVA	
# of Patients	N = 396	
Target Patients	The participant has a confirmed diagnosis of moderately to severely active CD	
Arms/Intervention	 Experimental: Induction Period: Vedolizumab + Upadacitinib: Participants will receive vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, 6 and 10 along with upadacitinib 45 mg, orally, once daily (QD) during the 12-week Induction Period. Placebo Comparator: Induction Period: Vedolizumab +Placebo: Participants will receive vedolizumab IV 300 mg infusion, at Weeks 0, 2, 6 and 10 along with upadacitinib matched placebo, orally, QD during the 12-week Induction Period. Experimental: Maintenance Period: Vedolizumab Monotherapy: Participants who achieve a CDAI reduction of ≥70 points from baseline at Week 12 will receive vedolizumab 300 mg IV infusion (monotherapy) every 8 weeks (Q8W) during the 40-week Maintenance Period. The Q8W vedolizumab monotherapy may be escalated to Q4W as per protocol-specified criteria. 	
Primary endpoint and key secondary endpoint(s)	 To evaluate whether dual targeted therapy (DTT, vedolizumab and upadacitinib) during induction improves clinical and endoscopic outcomes by Week 12, compared with vedolizumab monotherapy, in participants with moderately to severely active CD. To evaluate further the short-term clinical and endoscopic benefits of DTT during induction, compared with vedolizumab monotherapy, in participants with moderately to severely active CD. 	
Study start date	January 2025	

Study	<u>NCT06249555</u>	<u>NCT06257706</u>
Indication	Crohn's Disease (CD)	Crohn's Disease (CD)
Phase	Phase IV VOICE	Phase IV VECTORS
# of Patients	N = 300 (estimated)	N = 304 (estimated)
Target Patients	Participant is an adult 18 years of age or older with confirmed CD, as per standard clinical criteria which may include symptoms, endoscopy, histopathology, and imaging.	Adults aged 18 to 80 years with Moderately-to-severely active CD at baseline defined by a CDAI score of 220 to 450 inclusive and SES-CD, excl. the presence of narrowing component, \geq 6 (or \geq 4 for participants with isolated ileal disease)
Arms/ Intervention	 Two arm study: Group one will include participants who will be starting Vedolizumab as part of routine care. Dose, frequency and duration are not mandated as part of the study and are determined by the health care provider. Group two will include participants who will be starting an IL-23 antagonist as part of routine care. Dose, frequency and duration are not mandated as part of the study and are determined by the health care provider. 	 Group 1 will be treated over 48 weeks to achieve a target of corticosteroid-free IUS-based outcomes + clinical remission + biomarker remission. At Week 22 and 30, the IUS-based component of the target will be IUS response and at Week 38, the final treatment target will be TMH. Group 2 will be treated over 48 weeks to achieve a target of corticosteroid-free clinical remission + biomarker remission. Intervention: All participants will begin a vedolizumab induction regimen of 300 mg IV at Weeks 0, 2, 6, and 10 followed by vedolizumab 300 mg IV every 8 weeks starting at Week 14. Treatment may be modified at Weeks 22, 30, and/or 38 based on the results of the target assessment at each of these time points.
Primary endpoint and key secondary endpoint(s)	Time to meaningful clinical improvement in pain interference, defined as a \geq 2-point decrease in the PROMIS Pain Interference-SF T-score	Percentage of participants with Corticosteroid-free Endoscopic remission in group 1 and group 2 at week 48
Study start date	March 2024	August 2024

ADZYNMA (TAK-755): REPLACEMENT OF THE DEFICIENT ADAMTS13 ENZYME

Study	<u>NCT03393975</u>	<u>NCT05714969</u>
Indication	Congenital Thrombotic Thrombocytopenic Purpura (cTTP)	Immune Thrombotic Thrombocytopenic Purpura (iTTP)
Phase	Phase III	Phase IIb
# of Patients	N = up to 68	N = 40
Target Patients	Patients diagnosed with severe cTTP in prophylactic and on- demand treatment	Adult patients diagnosed with iTTP experiencing an acute event
Arms/Intervention	 Prophylaxis Treatment Cohort: 6 + 6 months cross over of TAK-755 vs SoC followed by 6 months TAK-755 extension Arm 1: TAK-755 followed by SOC Arm 2: SOC followed by TAK-755 (Patients are also eligible to enter the prophylaxis study upon completion of acute treatment) 	 Acute Phase: Arm 1: TAK-755 40 IU/kg BID Arm 2: TAK-755 80 IU/kg BID Post-acute Phase: 80 IU/kg 2-3x weekly (3 – 6-week duration)
Primary endpoint and key secondary endpoint(s)	 Primary: Incidence of acute TTP episodes in subjects receiving prophylactic treatment with either TAK-755 or SoC. 	 Primary: Incidence of adverse events, serious adverse events, and adverse events of special interest. Secondary: Achievement of clinical response without on-study plasma exchange.
Study start date	October 2017	March 2023

MARALIXIBAT (TAK-625): IBAT (ILEAL BILE ACID TRANSPORTER) INHIBITOR

Study	<u>NCT05543187</u>	<u>NCT05543174</u>
Indication	Progressive Familial Intrahepatic Cholestasis (PFIC)	Alagille Syndrome (ALGS)
Phase	Phase III Japan	Phase III Japan
# of Patients	N = 5	N = 7
Target Patients	Patients with Progressive Familial Intrahepatic Cholestasis	Patients with Alagille Syndrome
Arms/Intervention	TAK-625 orally, twice daily (BID) for 4 weeks as Dose Escalation Period. The dose in Dose Escalation Period will be increased weekly, 150 mcg/kilograms (kg), 300 mcg/kg, 450 mcg/kg, and 600 mcg/kg. After Dose Escalation Period, TAK-625 600 mcg/kg (or maximum tolerated dose [MTD]), orally, BID up to study completion	TAK-625 200 mcg per kilogram, orally, once daily for 1 week. After that, TAK-625 400 mcg per kilogram, orally, once daily after Week 1
Primary endpoint and key secondary endpoint(s)	 Primary: Change in the Average Morning ItchRO (Obs) Severity Score between Baseline and Average of Week 15 through Week 26 Key Secondary: Change in the Average Morning ItchRO (Obs) Frequency Score between Baseline and Average of Week 15 through Week 26 Change of Total sBA Levels from Baseline to Week 26 Percentage of Participants who Achieve sBA Well Control from Baseline through Week 26 Change in the ItchRO (Obs) Weekly Average Severity between Baseline and Average of Week 15 through Week 26 	 Primary: Change of Fasting Serum Bile Acid (sBA) Levels from Week 18 to Week 22 Key Secondary: Change from baseline to Week 18: Fasting sBA levels. Pruritus as measured by ItchRO (Obs): weekly average severity (based on daily maximum of morning and evening severity scores). Pruritus as measured by ItchRO (Obs): weekly average morning severity. Change from Week 18 to 22: Pruritus as measured by ItchRO (Obs): weekly average severity (based on daily maximum of morning and evening severity scores). Pruritus as measured by ItchRO (Obs): weekly average severity (based on daily maximum of morning and evening severity scores). Pruritus as measured by ItchRO (Obs): weekly average severity (based on daily maximum of morning and evening severity scores). Pruritus as measured by ItchRO (Obs): weekly average morning severity.
Study start date	lanuary 2023	lanuary 2023

ZASOCITINIB (TAK-279): *TYK2 – INHIBITOR, ORAL*

Study	<u>NCT06088043</u>	<u>NCT06108544</u>
Indication	Moderate-to-Severe Plaque Psoriasis	Moderate-to-Severe Plaque Psoriasis
Phase	Phase III LATITUDE PSORIASIS	Phase III LATITUDE PSORIASIS
# of Patients	N = 600	N = 1000
Target Patients	Patients with moderate-to-severe plaque psoriasis	Patients with moderate-to-severe plaque psoriasis
Arms/Intervention	 Arm 1: TAK-279 tablet for oral administration Arm 2: Apremilast for oral administration Arm 3: Matching placebo 	 Arm 1: TAK-279 tablet for oral administration Arm 2: Apremilast for oral administration Arm 3: Matching placebo incl. withdrawal and re-treatment period
Primary and Secondary Objective(s)	 Primary Objective: Evaluate efficacy of TAK-279 orally administered for 16 wks, compared to placebo Secondary Efficacy Objectives: Evaluate whether TAK-279 orally administered for 16 wks is superior to placebo Evaluate whether TAK-279 orally administered is superior to apremilast after 16, 24, and 52 weeks of treatment with TAK-279 or apremilast Secondary Safety Objective: Evaluate safety and tolerability of TAK-279 orally administered when compared to placebo and apremilast 	 Primary Objective: Evaluate efficacy of TAK-279 orally administered for 16 wks, compared to placebo Secondary Efficacy Objectives: Evaluate whether TAK-279 orally administered for 16 wks is superior to placebo Evaluate whether TAK-279 orally administered is superior to apremilast after 16 and 24 wks of treatment with TAK-279 or apremilast Evaluate maintenance and durability of efficacy of TAK-279 during withdrawal and re-treatment period Secondary Safety Objective: Evaluate safety and tolerability of TAK-279 orally administered when compared to placebo and apremilast Evaluate safety of retreatment after withdrawal

November 2023

ZASOCITINIB (TAK-279): *TYK2 – INHIBITOR, ORAL*

Study	<u>NCT05153148</u>	
Indication	Active Psoriatic Arthritis	
Phase	Phase II	
# of Patients	N = 260	
Target Patients	Participants with active psoriatic arthritis	
Arms/Intervention	 Regimen 1: TAK-279 at a dose of 5 mg will be orally administered once daily (QD) for 12 weeks. Regimen 2: TAK-279 at a dose of 15 mg will be orally administered once daily (QD) for 12 weeks. Regimen 3: TAK-279 at a dose of 30 mg will be orally administered once daily (QD) for 12 weeks. Regimen 4: Matching placebo, identical to TAK-279 but without active ingredient. 	
Primary endpoint and key secondary endpoint(s)	 Primary: Proportion of subjects achieving at least an American College of Rheumatology (ACR) 20 response [Time Frame: Day 1 to Week 16] 	
Study start date	January 2022	

ZASOCITINIB (TAK-279): *TYK2 – INHIBITOR, ORAL*

Study	<u>NCT06233461</u>	<u>NCT06254950</u>
Indication	Crohn's Disease	Ulcerative Colitis
Phase	Phase II	Phase II
# of Patients	N = 268	N = 207
Target Patients	Moderately to Severely Active Crohn's Disease	Moderately to Severely Active Ulcerative Colitis
Arms/Intervention	 Arm 1: TAK-279 Dose 1 for oral administration Arm 2: TAK-279 Dose 2 for oral administration Arm 3: TAK-279 Dose 3 for oral administration Arm 4: Matching placebo 	 Arm 1: TAK-279 Dose 1 for oral administration Arm 2: TAK-279 Dose 2 for oral administration Arm 3: Matching placebo
Primary endpoint and key secondary endpoint(s)	 Primary: Percentage of Participants With Endoscopic Response Based on Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12 Key secondary: Percentage of Participants Achieving Clinical Remission Based on the Crohn's Disease Activity Index (CDAI) at Week 12 Percentage of Participants Achieving Clinical response Based on CDAI at Week 12 Percentage of Participants Achieving Endoscopic Remission Based on SES-CD at Week 12 	 Primary: Percentage of Participants Achieving Clinical Remission at Week 12 Based on Modified Mayo Score (mMS) Key secondary: Percentage of Participants Achieving Clinical Response at Week 12 Based on Modified Mayo Score (mMS) Endoscopic improvement and Endoscopic remission based on mMES
Study start date	March 2024	June 2024

MEZAGITAMAB (TAK-079): ANTI-CD38 ANTIBODY

Study	<u>NCT04278924</u>	<u>NCT05174221</u>
Indication	Persistent/Chronic Primary Immune Thrombocytopenia (ITP)	IgA Nephropathy (IgAN)
Phase	Phase II	Phase Ib
# of Patients	N = 54	N = 16
Target Patients	Patients ≥18 years of age with persistent/chronic primary ITP	Patients ≥18 years of age with primary IgA Nephropathy in combination with stable background medication
Arms/Intervention	 Part A: 2 dose groups and placebo added to stable background therapy Arm A1: Matching placebo (n=8-12 pts) Arm A2: TAK-079 100 mg (n=8-12 pts) Arm A3: TAK-079 300 mg (n=8-12 pts) Part B: Following interim analysis. 1 dose group and placebo (600 mg) added to stable, standard background therapy. Arm B1: Matching placebo (n=4- 6 pts) Arm B2: TAK-079 600 mg (n=8-12 pts) 	 TAK-079 600 mg subcutaneous injection, once weekly for 8 weeks then once every 2 weeks for 16 weeks in the Main Study. Same dosing regimen will be repeated in Long-term extension (LTE) Retreatment Period.
Primary endpoint and key secondary endpoint(s)	 Primary: Percentage of patients with TEAEs including Grade 3 or higher events, SAEs, and AEs leading to TAK-079 discontinuation. 	 Primary: Percentage of participants with one or more TEAEs, Grade 3 or Higher TEAEs, SAEs, and AEs leading to TAK-079 discontinuation.
Study start date	November 2020	July 2022

FAZIRSIRAN (TAK-999): ALPHA-1 ANTITRYPSIN SILENCING RNAI

Study	<u>NCT05677971</u>	
Indication	Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD-LD)	
Phase	Phase III The Redwood Study	
# of Patients	N = 160	
Target Patients	Patients with PiZZ AATD-LD with METAVIR stage F2, F3, or F4 liver fibrosis.	
Arms/Intervention	 Arm 1: Fazirsiran subcutaneous injection at Day1, Week 4 and every 12 weeks thereafter Arm 2: Placebo 	
Primary endpoint and key secondary endpoint(s)	 Primary: Reduction from baseline of at least 1 stage of histologic fibrosis METAVIR staging in the centrally read liver biopsy in AATD-LD with METAVIR stage F2 and F3 fibrosis. Key Secondary: Evaluate percent change from baseline in intrahepatic Z-AAT protein. Evaluate the decrease in fibrosis in the centrally read liver biopsy in AATD-LD with METAVIR stage F2 – F4. Evaluate the impact on progression in disease (liver related clinical event). Evaluate changes from baseline in intrahepatic Z-AAT protein. Evaluate changes from baseline in serum Z-AAT protein polymer burden. Evaluate changes from baseline in portal inflammation. Evaluate changes from baseline in liver stiffness with Vibration-Controlled Transient Elastography (VCTE). Safety: Evaluate the safety and tolerability of Fazirsiran compared with placebo with an emphasis on central pulmonary function tests & CT densitometry yearly 	

TAK-227 / ZED1227: TRANSGLUTAMINASE INHIBITOR, PO

Study	EudraCT: <u>2020-004612-97</u> ¹	EudraCT: <u>2023-506150-21</u> ¹
Indication	Active Celiac Disease (symptoms and small intestinal mucosal injury consistent with active celiac disease despite a gluten free diet)	Active Celiac Disease (symptoms and small intestinal mucosal injury consistent with active celiac disease despite a gluten free diet)
Phase	Phase IIb	Phase IIb
# of Patients	N = 400	N = 92
Target Patients	Adults with celiac disease, with incomplete response to the gluten-free diet.	Adults with celiac disease, with incomplete response to the gluten-free diet.
Arms/Intervention	 Arm 1: TAK-227 10 mg 3 times daily, 30 minutes before each major meal Arm 2: TAK-227 25 mg 3 times daily, 30 minutes before each major meal Arm 3: TAK-227 50 mg once a day, 30 minutes before breakfast, Placebo capsules 30 minutes before lunch and before dinner Arm 4: Placebo capsules 3 times daily 30 minutes before each major meal 	 Arm 1: TAK-227 25 mg three times daily, 30 minutes before each major meal, plus thrice weekly study provided gluten exposure (approximately 500 mg gluten) Arm 2: Placebo capsules three times daily 30 minutes before each major meal, plus thrice weekly study provided gluten exposure (approximately 500 mg gluten)
Primary endpoint and key secondary endpoint(s)	 Primary: Improvement in histological findings AND Non-Stool GI Specific Symptom Score Change OR Diarrhea Severity Score (both measured with Celiac Disease Symptom Diary (CDSD)) Key Secondary: Change in histological findings; Change in CDSD GI Total Severity Score; Change in duodenal mucosal inflammation measured as the density of CD3- positive intraepithelial lymphocytes (IELs) 	 Primary: Improvement of celiac disease symptoms as assessed by Celiac Disease Symptom Diary (CDSD) in celiac disease subjects experiencing symptoms and having mucosal damage on a gluten-free diet. Key Secondary: Changes in duodenal mucosal morphology as measured by morphometry (villous height to crypt depth, VH:CrD), Changes in the severity of non-stool gastrointestinal (GI) symptoms (abdominal pain, bloating, nausea) as assessed by CDSD.
Study start date	August 2021	April 2024

ZAMAGLUTENASE (TAK-062): GLUTENASE, PO

Study	<u>NCT05353985</u>	
Indication	Active Celiac Disease (symptoms and small intestinal mucosal injury consistent with active celiac disease despite a gluten free diet)	
Phase	Phase II	
# of Patients	N = 357	
Target Patients	Adults and adolescents with celiac disease, with incomplete response to the gluten-free diet.	
Arms/Intervention	 Cohort 1: Arm 1: TAK-062 600 mg three times daily, plus thrice weekly study provided gluten exposure (approximately 500 mg gluten) Arm 2: Placebo three times daily, plus thrice weekly study provided gluten exposure (approximately 500 mg gluten) Cohort 2: Arm 1: TAK-062 placebo three times daily, plus thrice weekly study provided gluten exposure (approximately 500 mg gluten) Arm 2: TAK-062 placebo three times daily plus thrice weekly study provided gluten exposure (approximately 500 mg gluten) Arm 3: TAK-062 150 mg three times daily plus thrice weekly study provided gluten exposure (approximately 500 mg gluten) Arm 3: TAK-062 300 mg three times daily plus thrice weekly study provided gluten exposure (approximately 500 mg gluten) Arm 4: Placebo three times daily without study provided gluten exposure Arm 5: TAK-062 600 mg three times daily without study provided gluten exposure Arm 6: TAK-062 150 mg three times daily without study provided gluten exposure 	
Primary endpoint and key secondary endpoint(s)	 Primary: Change in GI symptom severity score (Celiac disease symptom diary) Key Secondary: Change in biopsy or histological findings using upper endoscopy 	
Study start date	December 2022	

TAK-101: NANOPARTICLE ENCAPSULATING GLIADIN, IV


Study	<u>NCT04530123</u>	
Indication	Celiac Disease	
Phase	Phase II	
# of Patients	N = 108	
Target Patients	Adult patients with history of biopsy-proven well-controlled celiac disease on a gluten-free diet for a minimum of 6 months.	
Arms/Intervention	 <u>Cohort 1:</u> Group A: Two infusion doses of placebo on Days 1 and 8 + 1 infusion dose of 25 μg/kg Gluten Epitopes (GE) TAK-101 at Week 24 Group B: One infusion dose of 2 mg/kg TAK-101 on Day 1 followed by 1 infusion dose of placebo on Day 8 + 1 infusion dose of 5 μg/kg GE TAK-101 at Week 24 Group C: Two infusion doses of 25 μg/kg GE TAK-101 on Days 1 and 8 + 1 infusion dose of 25 μg/kg GE TAK-101 at Week 24 Group D: Two infusion doses of placebo on Days 1 and 8 + 1 infusion dose of 25 μg/kg GE TAK-101 at Week 24 Group D: Two infusion doses of placebo on Days 1 and 8 + 1 infusion dose of 25 μg/kg GE TAK-101 at Week 24 Group E: One infusion dose of 50 μg/kg GE TAK-101 on Day 1 followed by 1 infusion dose of placebo on Day 8 + 1 infusion dose of 50 μg/kg GE TAK-101 at Week 24 Group F: Two infusion doses of 50 μg/kg GE TAK-101 on Days 1 and 8 + 1 infusion dose of 50 μg/kg GE TAK-101 at Week 24 Group F: Two infusion doses of 50 μg/kg GE TAK-101 on Days 1 and 8 + 1 infusion dose of 50 μg/kg GE TAK-101 at Week 24 Group G: Two infusion doses of 12.5 μg/kg GE TAK-101 on Days 1 and 8 + 1 infusion dose of 50 μg/kg GE TAK-101 at Week 24 	
Primary endpoint and key secondary endpoint(s)	 Primary: Reduction in Day 15 IFN-γ SFUs based on results of gliadin-specific ELISpot Key secondary: Safety and tolerability as assessed by AEs, IRs, CRS, physical examinations, vital signs, and clinical laboratory testing, including liver tests. Change in Celiac Disease Symptom Diary version 2.1 3-day average score from Day 1 to post-gluten challenge on Day 15 and Weeks 8, 14, and 20 Change from pre- to 4 hours post-gluten challenge in plasma IL-2 on Day 15 and Weeks 8, 14, and 20 	
Study start date	August 2022	

TAK-004: PEPTIDE AGONIST

Study	<u>NCT06236009</u>
Indication	Nausea & Vomiting
Phase	Phase I
# of Patients	N = 240
Target Patients	Healthy Volunteers
Arms/Intervention	 Part 1: TAK-004 subcutaneous injection single ascending dose / Placebo Part 2: TAK-004 subcutaneous injection multiple ascending dose / Placebo Part 3: TAK-004 subcutaneous injection expansion cohorts / Placebo
Primary endpoint and key secondary endpoint(s)	 Primary: Number of participants with adverse events. Key Secondary: Orthostatic changes in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) values from semi-recumbent to standing at 0.5 hours after first dose. Changes in semi-recumbent heart rate (HR) values at 2 hours after first dose. Number of participants with antidrug antibody (ADA) status.
Study start date	November 2024

Overview of Clinical Trials





OVEPOREXTON (TAK-861): OREXIN 2R AGONIST, ORAL

Study	<u>NCT05687903</u>	<u>NCT05687916</u>
Indication	Narcolepsy Type 1	Narcolepsy Type 2
Phase	Phase IIb	Phase IIb
# of Patients	N= 100	N= 60
Target Patients	Participants with Narcolepsy Type 1	Participants with Narcolepsy Type 2
Arms/Intervention	 TAK-861 Dose 1 TAK-861 Dose 2 TAK-861 Dose 3 TAK-861 Dose 4 Placebo 	 TAK-861 Dose 1 TAK-861 Dose 2 Placebo
Primary endpoint and key secondary endpoint(s)	 Primary: Change from Baseline to Week 8 in Mean Sleep Latency Secondary: Change from Baseline to Week 8 in Epworth Sleepiness Scale (ESS) Total Score Weekly Cataplexy Rate at Week 8 	 Primary: Change from Baseline to Week 8 in Mean Sleep Latency Secondary: Change from Baseline to Week 8 in Epworth Sleepiness Scale (ESS) Total Score
Study start date	January 2023	January 2023

OVEPOREXTON (TAK-861): OREXIN 2R AGONIST, ORAL

Study	<u>NCT06470828</u>
Indication	Narcolepsy Type 1 (NT1)
Phase	Phase III The First Light
# of Patients	N = 152
Target Patients	Participants with Narcolepsy Type 1
Arms/Intervention	 TAK-861 Dose 1 TAK-861 Dose 2 Placebo
Primary endpoint and key secondary endpoint(s)	 Primary: Change from Baseline to Week 12 in Mean Sleep Latency measured through MWT Key Secondary: Change from Baseline to Week 12 in Epworth Sleepiness Scale (ESS) Total Score Change from Baseline to Week 12 in Weekly Cataplexy Rate Change from Baseline in number of Lapses on the 3 Post Meridiem (PM) Psychomotor Vigilance Test (PVT) Session at Week 12 Change from Baseline in Patient Global Impression of Change (PGI-C) Score at Week 12 Change from Baseline in Narcolepsy Severity Scale for Clinical Trials (NSS-CT) Total Score at Week 12 Change from Baseline in Functional Impacts of Narcolepsy Instrument (FINI) Domain Scores at Week 12 Change from Baseline in Short Form-36 Survey (SF-36) Mental and Physical Component Scores at Week 12 Occurrence of at least 1 TEAE during the study including the follow-up period, as applicable.
Study start date	July 2024

DANAVOREXTON (TAK-925): OREXIN 2R AGONIST, IV

Study	<u>NCT05180890</u>	<u>NCT05814016</u>
Indication	Obstructive Sleep Apnea (OSA)	Postanesthesia Recovery
Phase	Phase I	Phase IIa
# of Patients	N = 18	N = 180
Target Patients	Patients With Obstructive Sleep Apnea	Moderate to severe obstructive sleep apnea patients undergoing general anesthesia for abdominal surgery
Arms/Intervention	Low doseHigh dosePlacebo	Danavorexton high doseDanavorexton low dosePlacebo
Primary endpoint and key secondary endpoint(s)	 Primary: Number of Participants With at Least one Treatment-emergent Adverse Event (TEAE) Secondary: Change From Baseline in Upper Airway Collapsibility Index (UACI) Apnea-Hypopnea Index (AHI) Observed During Overnight Polysomnographys (PSGs) 	 Primary: Number of Participants who Maintain Respiratory Stability for 120 Minutes in the Postanesthesia Care Unit Secondary (selected): Number of Episodes of Respiratory Instability per Participant Within 120 Minutes in the PACU PK parameters Number of Participants with At Least One Occurrence of Treatment-Emergent Adverse Events
Study start date	March 2022	May 2023

TAK-341: ALPHA-SYNUCLEIN ANTIBODY, IV

Study	<u>NCT05526391</u>
Indication	Multiple System Atrophy
Phase	Phase II
# of Patients	N = 138
Target Patients	Patients With Multiple System Atrophy
Arms/Intervention	Q4wk IV infusion of TAK-341 or Placebo (1:1)
Primary endpoint and key secondary endpoint(s)	 Primary: Change from Baseline in a Modified Unified Multiple System Atrophy Rating Scale Part I at Week 52 Secondary (selected): PK parameters Change From Baseline in Scales for Outcomes in Multiple System Atrophy - Autonomic Dysfunction Total Score and Clinical Global Impression-Severity Score

Study start date


November 2022

TAK-594 / DNL593: *PROGRANULIN PTV, IV AND SC*

Study	<u>NCT05262023</u> ¹
Indication	Frontotemporal Dementia
Phase	Phase I/II
# of Patients	N = 106
Target Patients	Healthy volunteers / Participants with symptomatic FTD
Arms/Intervention	 Part A: SRD in Healthy Participants Part B: Multiple doses in participants with symptomatic FTD harboring the GRN mutation Part C: optional 18-month OLE period available for all participants who complete Part B
Primary endpoint and key secondary endpoint(s)	 Primary: Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs) Incidence of treatment-emergent clinically significant abnormalities in safety laboratory values Change from baseline in vital sign measurements (systolic and diastolic blood pressure, heart rate, respiratory rate, body temperature) Change from baseline in electrocardiogram (ECG) results including PR, QRS, and QTCF intervals Incidence of treatment-emergent clinically significant abnormalities in physical/neurological examination findings Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS; Parts B and C only) Secondary: Serum PK
Study start date	February 2022

Overview of Clinical Trials





ICLUSIG (PONATINIB): BCR-ABL INHIBITOR

Study	<u>NCT02467270</u>	<u>NCT03589326</u>
Indication	Chronic myeloid leukemia (CML)	Ph+ acute lymphoblastic leukemia (ALL)
Phase	Phase II OPTIC	Phase III Ph+ALLCON
# of Patients	N = 283	N = 245
Target Patients	Patients with resistant chronic phase chronic myeloid leukemia	Patients with newly-diagnosed Ph+ ALL
Arms/Intervention	 Ponatinib 45 mg once daily Ponatinib 30 mg once daily Ponatinib 15 mg once daily 	 Cohort A: Ponatinib/reduced intensity chemotherapy until progressive disease (PD) or stem cell transplant (SCT) Cohort B: Imatinib/reduced intensity chemotherapy until PD or SCT
Primary endpoint and key secondary endpoint(s)	Primary: Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12 [Time Frame: 12 months after the first dose of study treatment]	 Primary: Number of participants with Minimal Residual Disease (MRD) - Negative Complete Remission (CR) [Time frame: From Cycle 1 through Cycle 3 (approximately 3 months) (Cycle length is equal to 28 days)] Secondary: EFS
Study start date	August 2015	January 2019

NINLARO (IXAZOMIB): ORAL PROTEASOME INHIBITOR

Study	<u>NCT03173092</u>	
Indication	Non-transplant eligible patients with newly diagnosed multiple myeloma	
Phase	Phase IV MM6	
# of Patients	N = 141	
Target Patients	Patients with multiple myeloma previously receiving a bortezomib-based induction. In-class (proteasome inhibitor) transition after 3 cycles of bortezomib-based therapy. PFS/OS follow up for up to 2.5 years.	
Arms/Intervention	 Ixazomib 4 mg + lenalidomide 25 mg + dexamethasone 40 mg IRd treatment to be given up to 39 cycles Transition from a bortezomib based regimen to IRD (ixazomib, lenalidomide, dexamethasone) may allow the long-term proteasome inhibition to be maximized while maintaining a manageable safety profile. 	
Primary endpoint and key secondary endpoint(s)	Primary: Progression Free Survival (PFS) at 2 years. Key secondary: Time to next therapy (TTNT), relative dose intensity (RDI) of the oral regimen, overall survival (OS), electronic patient reported outcomes (ePRO) and actigraphy (activity/sleep) data.	
Study start date	September 2017	
Publications	 Rifkin et al Blood Cancer Journal 2023; DOI 10.1038/s41408-023-00912-9 Richter et al JNCCN 2023; DOI: 10.6004/jnccn.2023.7058 Rifkin et al Future Oncology 2023; 10.2217/fon-2023-0272 Girnius et al. Blood (2023) 142 (Supplement 1): 6677 Boccia et al. EHA 2024 (abstract P1969) 	

MIRVETUXIMAB SORAVTANSINE (TAK-853): FOLATE RECEPTOR ALPHA (FRα) ANTIBODY DRUG CONJUGATE

Study	<u>NCT06390995</u>	<u>NCT05445778</u> ¹
Indication	Folate Receptor Alpha (FRα)-Positive Platinum-Resistant Ovarian Cancer (PROC)	Folate Receptor Alpha (FR α)-Positive Platinum-Sensitive Ovarian Cancer (PSOC)
Phase	Phase I/II	Phase III GLORIOSA
# of Patients	Phase 1: At least 3 (up to 9) patients; Phase 2: Approximately 22 patients	N = 418
Target Patients	Phase 1: Patients with FRα-positive advanced ovarian cancer or other solid tumor Phase 2 Patients with platinum-resistant ovarian cancer with high FRα expression, who have received 1 to 3 prior lines of therapy	Patients with recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression
Arms/ Intervention	 Single arm study Dose Level(s): Single-agent MIRV 6.0 mg/kg (adjusted ideal body weight) Q3W Route of Administration: Intravenous 	 Arm 1 (Experimental): Mirvetuximab Soravtansine (MIRV) plus Bevacizumab Dose Level(s): MIRV 6.0 mg/kg adjusted ideal body weight plus Bevacizumab 15mg/kg Q3W Route of Administration: Intravenous Arm 2 (Active Comparator): Bevacizumab monotherapy
Primary endpoint and key secondary endpoint(s)	 Primary: Phase 1: The number of patients with dose-limiting toxicities (DLTs) in Cycle 1. Phase 2: Objective response rate (ORR) assessed by investigator with RECIST 1.1. Secondary: Phase 1: PK parameters (e.g., C_{max}, AUC, t_{1/2}, CL, V_{ss}, and t_{max}.) Phase 2: Duration of response (DOR) assessed by investigator with RECIST 1.1, Observed plasma concentration, Number of patients with immunogenicity of MIRV 	 Primary: Progression-free survival (PFS) defined as the time from date of randomization until investigator-assessed progressive disease (PD) or death, whichever occurs first. Secondary: Overall survival (OS), Adverse events (AEs), Objective Response Rate (ORR), Assess Duration of response (DOR), Disease-free survival (DFS), Serum CA-125 response, Patient-reported outcome health-related quality of life (HRQoL) of disease-related symptoms
Study start date	June 2024	December 2022

Oncology

RUSFERTIDE (TAK-121): HEPCIDIN MIMETIC

Study	<u>NCT05210790</u> 1		
Indication	Polycythemia vera		
Phase	Phase III The VERIFY Study		
# of Patients	N = 293		
Target Patients	Patients with Polycythemia vera with confirmed Hct ≥45% and that is ≥3% higher than baseline Hct or Hct ≥48% who require phlebotomy on a frequent basis (≥3 PHL in 28 weeks prior to randomization or ≥5 PHL in 52 weeks prior to randomization)		
Arms/Intervention	 Part 1A: Randomized, double-blind, placebo-controlled, add-on parallel-group period for 32 weeks. Subjects randomized 1:1 in a blinded fashion to 32 weeks of add-on rusfertide or placebo treatment. Rusfertide or placebo will be added-on to each subject's ongoing therapy for PV. Randomization will be stratified by ongoing PV therapy. Part 1B: Open-label treatment phase during which all subjects who complete Part 1a will receive rusfertide for 20 weeks (Wk 32 thru Wk 52). Part 2: Long term extension for 104 weeks during which all subjects who complete Part 1b will continue to receive rusfertide. 		
Primary endpoint and key secondary endpoint(s)	 Primary: Proportion of patients achieving a response (Weeks 20-32 inclusive) who receive rusfertide compared to placebo. Response is defined as absence of PHL eligibility (Confirmed Hct ≥45% and that is ≥3% higher than baseline Hct or Hct ≥48%) Key Secondary: Mean number of phlebotomies between Weeks 0 through 32 (inclusive). Proportion of subjects with all Hct values <45% between Week 0 through Week 32 (inclusive). Mean change from baseline in total fatigue score based on PROMIS[®] Short Form 8a at Week 32. Mean change from baseline in total score based on the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 at Week 32. 		
Study start date	April 2022		

DAZOSTINAG (TAK-676): STING AGONIST

Study	<u>NCT04420884</u>	<u>NCT04879849</u>
Indication	Solid tumors	Solid tumors
Phase	Phase I/II	Phase I
# of Patients	N = 336	N = 34
Target Patients	 Dose escalation (Part 1): Adult patients with advanced or metastatic solid tumors Expansion cohorts (Parts 2 and 3): Adult patients with SCCHN 1L PD-L1+ or SCCHN 1L all comers Adult patients with 3L+ MSI-H/dMMR CRC or 3L MSS/pMMR CRC 	Adult patients with advanced or metastatic solid tumors
Arms/Intervention	 Part 1: Arm 1: Dose escalating single agent TAK-676, starting with safety lead-in at 0.1 mg IV on Days 1, 8, 15 in 21-day cycles, and capping at 2.5 mg IV on Days 1, 8 and 15 in a 21-day cycle. Arm 2: Dose escalating TAK-676 along above parameters in combination with fixed dose pembrolizumab at 200mg IV administered on D1 in a 21-day cycle. Parts 2 and 3: TAK-676 at RP2D level on Days 1, 8, and 15 in 21-day treatment cycles with fixed dose pembrolizumab at 200mg IV administered on D1 in a 21-day cycle. Part 2B only - starting with safety lead-in, addition of carboplatin/cisplatin and 5-FU on D1 in 21-day cycle. 	 Image-guided radiation therapy between Day -8 and Day -1 followed by fixed dose pembrolizumab at 200 mg IV administered on D1 of a 21-day cycle in combination with dose escalating TAK-676, starting at 0.2 mg IV and capping at 2.5 mg IV on Days 1, 8 and 21 in a 21-day cycle.
Primary endpoint and key secondary endpoint(s)	Primary: Safety and tolerability Secondary: Recommended Phase 2 dose (RP2D), overall response rate (ORR), progression free survival (PFS), overall survival (OS)	Primary: Safety and tolerability Secondary: Recommended Phase 2 dose (RP2D), overall response rate (ORR)
Study start date	August 2020	July 2021

TAK-186: *T-CELL ENGAGER*

-		
	nco	OCU
		1021
		-01

Study	<u>NCT04844073</u>	
Indication	Solid tumors	
Phase	Phase I/II	
# of Patients	N = 210	
Target Patients	Patients with unresectable, locally advanced or metastatic cancer	
Arms/Intervention	Single-arm, open label, MVC-101 (also known as TAK-186) - An EGFR x CD3 Conditional Bispecific Redirected Activation (COBRA) Protein This Phase 1/2, open-label study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated / recommended phase 2 dose (MTD/RP2D) of TAK-186. Dose escalation will occur in a 1+3 and then 3+3 design in patients with advanced solid tumors. Once the dose levels for expansion are determined, a Cohort Expansion Phase will be enrolled to further characterize safety and initial antitumor activity in patients with HNSCC, CRC or NSCLC.	
Primary endpoint and key secondary endpoint(s)	 Primary: Safety based upon incidence of treatment-emergent adverse events. Secondary: Pharmacokinetics, Pharmacodynamics, Immunogenicity measured by plasma anti-drug antibodies, and Radiographic anti-tumor activity 	
Study start date	March 2021	

TAK-280: *T-CELL ENGAGER*


Study	<u>NCT05220098</u>	
Indication	Solid tumors	
Phase	Phase I/II	
# of Patients	N = 142-182	
Target Patients	Patients with unresectable, locally advanced or metastatic cancer	
Arms/Intervention	Single-arm, open label, TAK-280 - An B7-H3 x CD3 Conditional Bispecific Redirected Activation (COBRA) Protein This Phase 1/2, open-label study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated/recommended dose for the expansion phase into solid tumor indications Dose escalation will utilize a BOIN design in patients with advanced solid tumors. Once the recommended doses for expansion (RDEs) is determined, people living with metastatic NSCLC, mCRPC and cutaneous melanoma will be enrolled in the cohort expansion phase, to further characterize safety and initial antitumor activity.	
Primary endpoint and key secondary endpoint(s)	 Primary: Tolerability and Safety based upon incidence of treatment-emergent adverse events. Secondary: Pharmacokinetics, Pharmacodynamics, Immunogenicity measured by incidence, titer and neutralizing potential of anti-drug antibodies, and radiographic anti-tumor activity. 	
Study start date	May 2022	

TAK-012: NON-ENGINEERED CELL THERAPY

Study	<u>NCT05886491</u>	
Indication	Relapsed/refractory acute myeloid leukemia (AML)	
Phase	Phase I/IIa	
# of Patients	N = 53	
Target Patients	Adult patients with relapsed or refractory acute myeloid leukemia	
Arms/Intervention	 During Phase 1 (sequential dose escalation), participants will be assigned to one of the following treatment groups each consisting of 3 to 6 participants to receive TAK-012 at one of the three dose levels: Dose 1, Dose 2, Dose 3. Upon completion of Phase 1, 1 to 2 dose levels will be selected for Phase 2a of the study. At the completion of Phase 2a of the study, a single dose may be selected by the sponsor and investigators as the recommended phase 2 dose (RP2D) for future study. 	
Primary endpoint and key secondary endpoint(s)	 Primary: Incidence of dose-limiting toxicities, treatment-emergent adverse events (AEs) and AEs of clinical interest 	
Study start date	July 2023	

Overview of Clinical Trials





ADYNOVATE (TAK-660): PEGYLATED RECOMBINANT FACTOR VIII

Study	<u>NCT02615691</u>	<u>NCT05707351</u>
Indication	Hemophilia A	Hemophilia A
Phase	Phase III	Phase III
# of Patients	N = 120	N = At least 30 evaluable subjects aged 12 to 65 years
Target Patients	Previously untreated patients (PUPs) < 6 years with severe hemophilia A (FVIII < 1%)	Previously treated patients with severe hemophilia A (FVIII <1%) in the Chinese population
Arms/Intervention	Single group assignment	Single group assignment
Primary endpoint and key secondary endpoint(s)	 Primary: Incidence of inhibitor development to FVIII (≥ 0.6 Bethesda unit (BU)/mL using the Nijmegen modification) Key Secondary: Safety 1. Binding IgG and IGM antibodies to FVIII, PEG-FVIII and PEG 2. Adverse events (AEs) and serious adverse events (SAEs) Efficacy 3. Annualized Bleeding Rate (ABR) for prophylactic and on demand treatment 4. Overall hemostatic efficacy rating at 24 hours after initiation of treatment and resolution of bleed 5. incremental recovery (IR) of Adynovate at baseline and over time ITI 6. Success rate of ITI therapy with BAX-855 	 Primary: Total Annualized Bleeding Rate (ABR) Key Secondary: Efficacy 1. Annualized bleeding rates based on bleed site and cause 2. Number of infusions and weight-adjusted consumption of Adynovate per week and month during the prophylactic treatment period Safety 3. Occurrence of AEs and SAEs, total incidence, by severity, and by causality Pharmacokinetics 4. Factor VIII activity (1-stage clotting assay) in PK samples collected for single-dose and steady-state PK assessments
Study start date	November 2015	April 2023

VONVENDI (TAK-577): RECOMBINANT VON WILLEBRAND FACTOR


Study	<u>NCT02932618</u>	<u>NCT05582993</u>
Indication	Pediatric On-demand and Surgery	Pediatric Prophylaxis
Phase	Phase III	Phase III
# of Patients	N = 23 (On-demand) N = 12 (Elective and Emergency surgery)	N =24
Target Patients	Severe von Willebrand Disease	Severe von Willebrand Disease
Arms/Intervention	Arm A: On-demandArm B: Elective and emergency surgery	 Cohort 1 participants ≥12 to <18 years of age Cohort 2 participants ≥6 to <12 years of age Cohort 3 participants 0 to <6 years of age
Primary endpoint and key secondary endpoint(s)	 Primary: Hemostatic efficacy and safety of rVWF, with or without ADVATE, in the treatment and control of nonsurgical bleeding events Key secondary: Hemostatic efficacy assessed after the last perioperative rVWF infusion 	 Primary: Annualized bleeding rate (ABR) with intra-patient control (on- study compared to historical) for all (both spontaneous and traumatic) bleeding episodes classified by the investigator during prophylactic treatment with rVWF. Key Secondary: Safety Endpoints Overall Hemostatic Efficacy Rating of Breakthrough Bleed Treatment at Resolution of the Bleeding Episode
Study start date	October 2016	January 2024

LIVTENCITY (MARIBAVIR): ORAL VIRAL PROTEIN KINASE INHIBITOR

Study	<u>NCT05319353</u>	
Indication	Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)	
Phase	Phase III	
# of Patients	N = 80	
Target Patients	Treatment of Children and Teenage Transplant Recipients With CMV Infection	
Arms/Intervention	Cohort 1: Maribavir 400mg BID (body weight ≥ 25kg) or 200mg BID (body weight 10-25 kg) participants 12 to <18 years of age Cohort 2: Maribavir 400mg BID (body weight ≥ 25kg) or 200mg BID (body weight 10-25 kg) participants ≥6 to <12 years of age Cohort 3: Maribavir participants 0 to <6 years of age	
Primary endpoint and key secondary endpoint(s)	 Primary: Pharmacokinetic characterization of Maribavir in pediatric HSCT and SOT subjects from 0 years to <18 years of age Safety and tolerability Secondary: Confirmed clearance of plasma CMV DNA at week 8 Maintenance of confirmed CMV viremia clearance achieved at the end of Study Week 8 through Week 12, Week 16 and Week 20 	
Study start date	November 2023	

Overview of Clinical Trials





HYQVIA (TAK-771): IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE

Study	<u>NCT05150340</u>	<u>NCT05084053</u>
Indication	Primary Immunodeficiency Diseases (PID)	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Multifocal Motor Neuropathy (MMN)
Phase	Phase III	Phase III
# of Patients	N = 15	N = 21
Target Patients	Japanese persons ages 2 and older with primary immunodeficiency diseases	Japanese persons ages 18 and older with definite or probable CIDP or MMN
Arms/Intervention	 Experimental: Epoch 1: TAK-771 Ramp up Period Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution. The dose of 10% IGI will be increased from 1/3 of full dose to full dose in 3 weeks for participants who will receive TAK-771 once every 3 week, or from 1/4 of full dose to full dose in 6 weeks for participants who will receive TAK-771 once every 4 week. Experimental: Epoch 2: TAK-771 Treatment Period Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 3, or 4 weeks for up to Week 24. 	 Cohort 1 (TAK-771 for CIDP Participants): rHuPH20 SC dose of 80 U/g IgG followed by SC infusion of 10% IGI within 10 min of completion of infusion of rHuPH20 solution, every 2,3,4 weeks Cohort 2 (TAK-771 for MMN Participants): rHuPH20 SC dose of 80 U/g IgG followed by SC infusion of 10% IGI within 10 min of completion of infusion of rHuPH20 solution, every 2,3,4 weeks
Primary endpoint and key secondary endpoint(s)	Primary : Serum trough levels of total IgG antibodies after administration of TAK-771 Secondary: PK, safety and tolerability, efficacy, and disease activity and HRQoL.	Primary: % of participants with CIDP who experience relapse in 6 months; change in maximum grip strength in the more affected hand in 6 months for MMN participants Secondary: safety, and CIDP/MMN health-related metrics.
Study start date	March 2022	January 2022

HYQVIA (TAK-771): IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE

<u>NCT05513586</u>	
Primary Immunodeficiency Diseases (PID)	
Phase III	
N = 10	
Japanese persons ages 2 and older with primary immunodeficiency diseases	
 This study is an extension study for participants with primary immunodeficiency disorders who were previously treated with TAK-771 in the TAK-771-3004 study. They must have completed that study or be about to complete it before joining this study. Participants will continue treatment with TAK-771 in this study. The main aim of this study is to check for side effects from long-term treatment with TAK-771. This medicine is not yet licensed in Japan, so participants will be treated with TAK-771 until it becomes commercially available. 	
 Primary: Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs) [Time Frame: Up to 3 years] TEAEs are defined as AEs with onset after date-time of first dose of investigational drug or medical conditions present prior to the start or investigational drug but increased in severity or relationship after date-time of first dose of investigational drug. Percentage of Participants who Develop Anti-rHuPH20 Binding Antibody Titers of Greater Than or Equal to 1:160 and who Develop Neutralizing Antibodies to rHuPH20 [Time Frame: Up to 3 years] 	

Study start date

September 2022

TAK-881 (FACILITATED SCIG 20%): IMMUNE GLOBULIN SC (HUMAN), **20% SOLUTION WITH RECOMBINANT HUMAN HYALURONIDASE**

Study	<u>NCT05755035</u>
Indication	Primary Immunodeficiency Diseases (PIDD)
Phase	Phase III
# of Patients	N = 56
Target Patients	Participants aged 2 and older with PIDD
Arms/Intervention	 Experimental: Randomized Crossover Treatment Epoch: TAK-881 followed by HYQVIA (Sequence 1) Participants aged >=16 years will receive 6 or 8 full doses of TAK-881 followed by 6 or 8 full doses HYQVIA in sequence 1 Experimental: Randomized Crossover Treatment Epoch: HYQVIA followed by TAK-881 (Sequence 2) Participants aged >=16 years will receive 6 or 8 full doses of HYQVIA followed by 6 or 8 full doses of TAK-881 in Sequence 2 Experimental: Non-Randomized Treatment Epoch: TAK-881 Participants aged 2 to <16 years will receive 6 or 8 full doses of TAK-881.
Primary endpoint and key secondary endpoint(s)	 Primary: Area Under the Curve during the dosing Interval at steady-state (AUC0-tau;ss) of TAK-881 and HYQVIA based on total IgG levels Key Secondary: Efficacy parameters including: (1) Annualized rate of all infections, (2) Annualized rate of acute serious bacterial infections (ASBIs), (3) Annualized rate of episodes of fever, (4) Time to first ASBI, and (5) Duration of infections Healthcare resource utilization (HRU) parameters including: (1) Days not able to go to school, work, daycare, or to perform normal daily activities due to infection or other illnesses or treatment, (2) Days on antibiotics, (3) Number of hospitalizations, indication for the hospitalization (infection or other illnesses) and days hospitalized, (4) Number of acute physician visits (office and emergency room) due to infection or other illnesses. PK parameters including: (1) Pharmacokinetics at steady-state including maximum concentration (Cmax), time of Cmax (Tmax), terminal half-life (t1/2), apparent clearance (CL/F), apparent volume of distribution (Vz/F), and AUC0-∂,ss/week based on total IgG levels, (2) Trough level of total IgG, (3) Trough level of IgG subclasses and antigen-specific, and (4) IgG antibodies Safety, tolerability and immunogenicity parameters including: (1) Occurrence of treatment-emergent adverse events (TEAEs), (2) Occurrence of infusion withdrawals, interruptions, and infusion rate reductions due to TAK-881-related TEAEs, and (3) Occurrence of positive binding (defined as titer ≥1:160) and neutralizing antibodies to rHuPH20
Study start date	November 2023

TAK-330: PROTHROMPLEX


Study	<u>NCT05156983</u>
Indication	Coagulation Disorder: Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation
Phase	Phase III
# of Patients	N = 328
Target Patients	Patients >18 years of age currently on Factor Xa inhibitor requiring urgent surgery/invasive procedure
Arms/Intervention	Adaptive parallel group sequential design Participants will receive PROTHROMPLEX TOTAL 25 international unit per kilogram (IU/kg) single intravenous infusion on Day 1 (prior to surgery). An additional dose of 25 IU/kg PROTHROMPLEX TOTAL can be administered during the surgery if deemed necessary by the surgeon. The total dose of PROTHROMPLEX TOTAL administered to the participant should not exceed 50 IU/kg or 5,000 IU, whichever is smaller. Active Comparator: 4F-PCC. Participants will receive 4F-PCC (excluding Prothromplex total and activated 4F-PCC) as SOC on Day 1 (prior to surgery). The dose and infusion speed of the SOC 4F-PCC will be based on local institutional protocols. An additional dose of SOC 4F-PCC not exceeding label specified limits can be given during the surgery if required. Intervention: Prothromplex total 25 IU/kg single IV on day 1 and an additional dose of 25 IU/kg if required
Primary endpoint and key secondary endpoint(s)	 Primary: Occurrence of intraoperative effective hemostasis assessed at the end of the surgery/invasive procedure based on the surgeon's assessment using the Four Point Intraoperative Hemostatic Efficacy Scale Key Secondary: Occurrence of postoperative effective hemostasis assessed at 24 hours after the end of investigational product infusion (TAK-330 or comparator 4F-PCC) based on the surgeon's assessment using the Four Point Postoperative Hemostatic Efficacy Scale. Occurrence of intraoperative effective hemostasis assessed at the end of the surgery/invasive procedure based on the surgeon's assessment using the Hemostatic Efficacy Rating Algorithm. Safety/tolerability and other measures
Study start date	August 2022

GLOVENIN-I (TAK-961): IMMUNE GLOBULIN INFUSION 5% (HUMAN)

Study	<u>NCT05177939</u>
Indication	Autoimmune Encephalitis (AE)
Phase	Phase III
# of Patients	N = 40
Target Patients	Japanese Subjects with Autoimmune Encephalitis Refractory to Steroid Pulse Therapy
Arms/Intervention	 Drug: NPB-01NPB-01 will be administered for the treatment of autoimmune encephalitis Other Name: Intravenous immunoglobulin Drug: NPB-01-MENPB-01-ME will be administered for the treatment of autoimmune encephalitis Other Name: methylprednisolone sodium succinate
Primary endpoint and key secondary endpoint(s)	 Primary: A responder is defined as a patient whose CASE score at Week 4 of the post-treatment follow-up period after treatment with investigational product improved by 40% or more compared to the pre-treatment period. Secondary: The change in CASE score at each time point after the start of treatment with investigational product compared with that on Day 8 of the pretreatment period will be compared between the arms. Changes in CASE scores divided into three segments (0 -4: excellent, 5 -9: moderate, 10 -27: poor) will also be compared. In addition, the period until CASE score becomes 4 points or less after the start of treatment with investigational product will be checked. Changes in mRS at each time point after the start of investigational product treatment compared with Day 8 of the pretreatment period will be compared between the arms. To compare the change in GCS at each time point after the start of investigational product with that on Day 8 of the pretreatment period between the arms. The change in MMSE-J at each time point after the start of investigational product as compared with Day 8 of the pretreatment period will be compared between the arms. The change in FAB at each time point after the start of investigational product as compared with Day 8 of the pretreatment period will be compared between the arms.
Study start date	April 2022

Overview of Clinical Trials





QDENGA (TAK-003): LIVE ATTENUATED TETRAVALENT VACCINE FOR PREVENTION OF DENGUE DISEASE

Study	<u>NCT02747927</u>
Indication	The prevention of dengue fever of any severity caused by any dengue virus serotype in individuals 4 years to 60 years of age
Phase	Phase III Tetravalent Immunization against Dengue Efficacy Study (TIDES)
# of Patients	N = 20,100
Target Patients	Healthy children aged 4 to 16-year-old in dengue-endemic countries in Latin America and Asia
Arms/Intervention	• Randomized 2:1 to receive either TAK-003 or placebo on Day 1 and Day 90
Primary endpoint and key secondary endpoint(s) to be met per Trial Protocol	Primary: ≥70% efficacy against all symptomatic dengue fever caused by any strain Secondary: ≥70% efficacy individual strains ≥60% efficacy in seronegatives Safety: Comparable to other live attenuated viral vaccines (e.g., MMR, YF, Varicella) No disease enhancement in partially protected individuals
Study start date	September 2016
Publications	 Tricou V, et al. The Lancet Global Health. 2024. López-Medina E, et al. The Journal of Infectious Diseases. 2020. Biswal S, et al. Clinical Infectious Disease. 2021

Vaccines



Better Health, Brighter Future

© 2025 Takeda Pharmaceutical Company Limited. All rights reserved.